Clinical Trial Update: Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Tucidinostat in combination with CHOP for newly diagnosed peripheral T-cell lymphoma with follicular helper T-cell phenotype; current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Tucidinostat (tucidinostat)

Snippet

Sponsor: Chipscreen Biosciences, Ltd. | Conditions: Lymphoma, T-Cell, Peripheral | Phase 3 | Status: RECRUITING